Ashish C. Bhatia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ashish C. Bhatia has a total of 209 co-authors. Here are the top co-authors by number of shared publications:
Shraddha Desai
The Dermatology Institute of DuPage Medical Group
5 shared publicationsJeffrey T.S. Hsu
4 shared publications- Murad Alam
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
4 shared publications Jeffrey S. Dover
Skincare Physicians Chestnut Hill Massachusetts USA
3 shared publications- Jeffrey Steven Dover
SkinCare Physicians, Chestnut Hill, Massachusetts
3 shared publications Robert T. Brodell
Department of Dermatology, University of Mississippi Medical Center, Jackson6Department of Dermatology, University of Rochester School of Medicine and Dentistry, Rochester, New York
3 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (11)
Clinical Evidence for Macrocystis pyrifera Ferment‐Containing Serum in Barrier Repair and Skin Tone Improvement
Background: Skin aging arises from intrinsic factors and is accelerated by extrinsic factors such as ultraviolet exposure and pollution, leading to inflammation, barrier impairment, and pigmentary changes. Energy‐based devices and chemical peels are widely used for facial rejuvenation, but post‐procedural recovery remains challenging due to barrier disruption and risk of dyschromia. Aims: This review evaluates the clinical evidence for Macrocystis pyrifera ferment (MPF)‐containing serum as an adjunctive skincare approach to support pre‐ and post‐procedure recovery, focusing on anti‐inflammatory effects, barrier repair, and pigmentary improvement. Methods: A panel of eight expert dermatologists reviewed clinical data on MPF and MPF‐containing serum, focusing on its potential applications in cosmetic dermatology. This manuscript presents the clinical evidence alongside insights from the panel discussion. Results: In a clinical erythema model, pretreatment with MPF significantly reduced erythema and accelerated recovery from irritation. Twice‐daily application of MPF‐containing serum improved hydration and reduced transepidermal water loss (TEWL), with moisturization increasing by 14% at Week 4 and 16% at Week 8, and TEWL decreasing by 11% at Week 8. Tape‐stripping studies confirmed a 30% improvement in barrier resilience at Week 8. In a trial of 52 women (ages 20–62, Fitzpatrick I–VI), twice‐daily application of MPF‐containing serum progressively improved post‐inflammatory erythema and hyperpigmentation, achieving nearly a 50% reduction in spot intensity and contrast by Week 12. Benefits were measurable as early as Week 2, and all participants demonstrated improvement by study end. Conclusions: MPF‐containing serum demonstrates anti‐inflammatory, barrier‐strengthening, and dyschromia‐improving properties, making it a safe and effective adjunct to dermatologic procedures. While current findings support its utility in post‐procedural care, further large‐scale, diverse clinical trials are warranted.
- 15 November 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (11)
Open AccessClinical Evidence for Macrocystis pyrifera Ferment‐Containing Serum in Barrier Repair and Skin Tone Improvement
Background: Skin aging arises from intrinsic factors and is accelerated by extrinsic factors such as ultraviolet exposure and pollution, leading to inflammation, barrier impairment, and pigmentary changes. Energy‐based devices and chemical peels are widely used for facial rejuvenation, but post‐procedural recovery remains challenging due to barrier disruption and risk of dyschromia. Aims: This review evaluates the clinical evidence for Macrocystis pyrifera ferment (MPF)‐containing serum as an adjunctive skincare approach to support pre‐ and post‐procedure recovery, focusing on anti‐inflammatory effects, barrier repair, and pigmentary improvement. Methods: A panel of eight expert dermatologists reviewed clinical data on MPF and MPF‐containing serum, focusing on its potential applications in cosmetic dermatology. This manuscript presents the clinical evidence alongside insights from the panel discussion. Results: In a clinical erythema model, pretreatment with MPF significantly reduced erythema and accelerated recovery from irritation. Twice‐daily application of MPF‐containing serum improved hydration and reduced transepidermal water loss (TEWL), with moisturization increasing by 14% at Week 4 and 16% at Week 8, and TEWL decreasing by 11% at Week 8. Tape‐stripping studies confirmed a 30% improvement in barrier resilience at Week 8. In a trial of 52 women (ages 20–62, Fitzpatrick I–VI), twice‐daily application of MPF‐containing serum progressively improved post‐inflammatory erythema and hyperpigmentation, achieving nearly a 50% reduction in spot intensity and contrast by Week 12. Benefits were measurable as early as Week 2, and all participants demonstrated improvement by study end. Conclusions: MPF‐containing serum demonstrates anti‐inflammatory, barrier‐strengthening, and dyschromia‐improving properties, making it a safe and effective adjunct to dermatologic procedures. While current findings support its utility in post‐procedural care, further large‐scale, diverse clinical trials are warranted.
- Open Access
- 2 September 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (9) , e71115
Next‐Generation Dual 1550‐nm Erbium Glass Fiber and 1927‐nm Thulium Fiber Non‐Ablative Fractional Laser System: Provider and Patient Perspectives
- 2 September 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (9) , e71115
Open AccessNext‐Generation Dual 1550‐nm Erbium Glass Fiber and 1927‐nm Thulium Fiber Non‐Ablative Fractional Laser System: Provider and Patient Perspectives
- Open Access
- 1 September 2026
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 58 (9) , 796-801
Report of Adverse Events Associated With Cutaneous Procedures: Update From the CAPER Registry
Objectives: To systematically evaluate submissions to the CAPER database by analyzing procedural context, characteristics of reported adverse events (AEs), and provider involvement in order to identify patterns with potential implications for patient safety. Methods: A retrospective review of all reports submitted to the CAPER database from March 2021 to August 2025 was conducted, categorizing cases by procedure type, reported AE, and provider involved. Results: In total, 199 reports describing 298 AEs across 35 various cutaneous procedures were submitted to the CAPER registry from March 2021 to August 2025. Dermatologists performed 62% of reported procedures, while non‐dermatologist physicians, non‐physicians, and unknown providers accounted for 38%. Filler injections, ablative laser resurfacing, and non‐ablative laser treatments were the most frequently reported procedures. Although dermatologists performed most procedures represented in the registry, 51% of reported AEs were associated with procedures performed by non‐dermatology providers. Erythema and scarring were among the most frequently reported AEs, while rare but serious events, including vascular compromise and necrosis, were reported following injectable and energy‐based procedures performed by a variety of provider types, including non‐physicians. Conclusions: The CAPER registry provides valuable insight into AEs associated with cutaneous procedures and may help identify emerging safety concerns related to new devices or techniques. Broader engagement with AE reporting systems may inform best practices and improve patient safety, particularly as cutaneous procedures increasingly occur outside traditional clinical settings.
- 1 September 2026
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 58 (9) , 796-801
Open AccessReport of Adverse Events Associated With Cutaneous Procedures: Update From the CAPER Registry
Objectives: To systematically evaluate submissions to the CAPER database by analyzing procedural context, characteristics of reported adverse events (AEs), and provider involvement in order to identify patterns with potential implications for patient safety. Methods: A retrospective review of all reports submitted to the CAPER database from March 2021 to August 2025 was conducted, categorizing cases by procedure type, reported AE, and provider involved. Results: In total, 199 reports describing 298 AEs across 35 various cutaneous procedures were submitted to the CAPER registry from March 2021 to August 2025. Dermatologists performed 62% of reported procedures, while non‐dermatologist physicians, non‐physicians, and unknown providers accounted for 38%. Filler injections, ablative laser resurfacing, and non‐ablative laser treatments were the most frequently reported procedures. Although dermatologists performed most procedures represented in the registry, 51% of reported AEs were associated with procedures performed by non‐dermatology providers. Erythema and scarring were among the most frequently reported AEs, while rare but serious events, including vascular compromise and necrosis, were reported following injectable and energy‐based procedures performed by a variety of provider types, including non‐physicians. Conclusions: The CAPER registry provides valuable insight into AEs associated with cutaneous procedures and may help identify emerging safety concerns related to new devices or techniques. Broader engagement with AE reporting systems may inform best practices and improve patient safety, particularly as cutaneous procedures increasingly occur outside traditional clinical settings.
- Open Access
- 2 March 2026
- Published by Springer Nature in Cureus
- Vol. 18 (3)
Clinical Outcomes Following Dual-Frequency Noninvasive Monopolar Radiofrequency Treatment for Facial Laxity and Lower Face Lifting: A Prospective Multicenter Study
Introduction Facial aging is a common dermatological and plastic surgical concern. As patients today wish to avoid surgical intervention, noninvasive monopolar radiofrequency (NMRF) can be a useful tool to address this concern, but results have varied by target depth. A dual-frequency NMRF system (6.78 MHz and 2 MHz) is designed to support depth-dependent tissue heating across dermal and subdermal planes. This study aimed to evaluate short-term clinical outcomes and safety in a prospective multicenter trial. Methods Thirty-nine subjects at four clinical sites completed the study. The protocol allowed up to three treatments spaced four weeks apart; however, all subjects completed the study after two sessions. Treatments were delivered at three different depths (shallow, middle, and deep), as indicated by the target condition and facial anatomical zone. Standardized clinical photography was taken at baseline, 30- and 90-day timepoints. A five-point Global Aesthetic Improvement Scale (GAIS) was assessed by the principal investigators at the 30- and 90-day assessments, and patients subjectively scored their satisfaction using a study-specific patient satisfaction score (PSS; six-point scale). GAIS results were evaluated for statistical significance; satisfaction was summarized descriptively with exact 95% CIs. Any adverse events were documented. Results A total of 39 subjects received two treatment sessions. Clinician-scored GAIS achieved three or above by 84.6% (33/39; 95% CI, 69.5-94.1) of subjects at 30-day and 92.3% (36/39; 95% CI, 79.1-98.4) of subjects at 90-day timepoints (p=0.0293 and 0.0008, respectively). Patient satisfaction was also high, scoring of four or above for 79.5% of participants at 30-day (31/39; 95% CI, 64.5-89.2%) and 84.6% at 90-day (33/39; 95% CI, 70.3-92.8%). There were no long-lasting adverse events. Conclusion Dual-frequency NMRF, applied with depth-dependent settings in this study, was associated with significant short-term improvement and high satisfaction at 30 and 90 days, with no persistent adverse events. These findings support further evaluation of this noninvasive RF approach for facial aging.
- 2 March 2026
- Published by Springer Nature in Cureus
- Vol. 18 (3)
Open AccessClinical Outcomes Following Dual-Frequency Noninvasive Monopolar Radiofrequency Treatment for Facial Laxity and Lower Face Lifting: A Prospective Multicenter Study
Introduction Facial aging is a common dermatological and plastic surgical concern. As patients today wish to avoid surgical intervention, noninvasive monopolar radiofrequency (NMRF) can be a useful tool to address this concern, but results have varied by target depth. A dual-frequency NMRF system (6.78 MHz and 2 MHz) is designed to support depth-dependent tissue heating across dermal and subdermal planes. This study aimed to evaluate short-term clinical outcomes and safety in a prospective multicenter trial. Methods Thirty-nine subjects at four clinical sites completed the study. The protocol allowed up to three treatments spaced four weeks apart; however, all subjects completed the study after two sessions. Treatments were delivered at three different depths (shallow, middle, and deep), as indicated by the target condition and facial anatomical zone. Standardized clinical photography was taken at baseline, 30- and 90-day timepoints. A five-point Global Aesthetic Improvement Scale (GAIS) was assessed by the principal investigators at the 30- and 90-day assessments, and patients subjectively scored their satisfaction using a study-specific patient satisfaction score (PSS; six-point scale). GAIS results were evaluated for statistical significance; satisfaction was summarized descriptively with exact 95% CIs. Any adverse events were documented. Results A total of 39 subjects received two treatment sessions. Clinician-scored GAIS achieved three or above by 84.6% (33/39; 95% CI, 69.5-94.1) of subjects at 30-day and 92.3% (36/39; 95% CI, 79.1-98.4) of subjects at 90-day timepoints (p=0.0293 and 0.0008, respectively). Patient satisfaction was also high, scoring of four or above for 79.5% of participants at 30-day (31/39; 95% CI, 64.5-89.2%) and 84.6% at 90-day (33/39; 95% CI, 70.3-92.8%). There were no long-lasting adverse events. Conclusion Dual-frequency NMRF, applied with depth-dependent settings in this study, was associated with significant short-term improvement and high satisfaction at 30 and 90 days, with no persistent adverse events. These findings support further evaluation of this noninvasive RF approach for facial aging.
- Open Access
- 5 February 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (2) , e70686
In Vitro, Ex Vivo and Clinical Trial of Brightening Serum Using a Novel Delivery System on Subjects With Moderate to Severe Dyschromia
Background/Aims: Pigmentary problems are common and can arise from sun exposure, skin inflammation, changes in hormones, and certain medications. Because they are visible, these pigmentary problems can be very distressing for individuals, and they are often challenging to manage. Three studies were conducted, ex vivo, in vitro, and in vivo. Subjects/Methods: An in vitro study of brightening/lightening in skin models; an ex vivo skin study using Raman spectroscopy; and a 12‐week clinical study of a novel complexion brightening serum with Tiered‐Release Vesicle (CBS‐TRV) delivery technology in adults with moderate to severe photodamage and uneven skin tone. Assessments included clinical grading, melanin and erythema measurements by Mexameter, digital imaging, and a patient self‐assessment questionnaire. Standard safety and tolerability assessments were also performed. Results: The in vitro 3D skin study showed that a 2 μL/cm 2 application of CBS‐TRV (the recommended and clinical application volume) slowed melanin production by 37.5% compared to untreated tissues after 2 weeks. Furthermore, Raman spectroscopy provided evidence for tranexamic acid penetration into the epidermis of ex vivo human skin. Clinical grading revealed significant improvements at the majority of visits, which were accompanied by improvements of erythema index and melanin index on mexameter. In addition, subjects provided positive feedback regarding the clinical results as well as the formulation's aesthetics. Finally, the CBS‐TRV product was safe and well tolerated. Conclusions: The multiple active ingredients in CBS‐TRV target melanogenesis in a variety of ways, and both in vitro and clinical studies demonstrated significant improvements in skin tone and pigmentation.
- 5 February 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (2) , e70686
Open AccessIn Vitro, Ex Vivo and Clinical Trial of Brightening Serum Using a Novel Delivery System on Subjects With Moderate to Severe Dyschromia
Background/Aims: Pigmentary problems are common and can arise from sun exposure, skin inflammation, changes in hormones, and certain medications. Because they are visible, these pigmentary problems can be very distressing for individuals, and they are often challenging to manage. Three studies were conducted, ex vivo, in vitro, and in vivo. Subjects/Methods: An in vitro study of brightening/lightening in skin models; an ex vivo skin study using Raman spectroscopy; and a 12‐week clinical study of a novel complexion brightening serum with Tiered‐Release Vesicle (CBS‐TRV) delivery technology in adults with moderate to severe photodamage and uneven skin tone. Assessments included clinical grading, melanin and erythema measurements by Mexameter, digital imaging, and a patient self‐assessment questionnaire. Standard safety and tolerability assessments were also performed. Results: The in vitro 3D skin study showed that a 2 μL/cm 2 application of CBS‐TRV (the recommended and clinical application volume) slowed melanin production by 37.5% compared to untreated tissues after 2 weeks. Furthermore, Raman spectroscopy provided evidence for tranexamic acid penetration into the epidermis of ex vivo human skin. Clinical grading revealed significant improvements at the majority of visits, which were accompanied by improvements of erythema index and melanin index on mexameter. In addition, subjects provided positive feedback regarding the clinical results as well as the formulation's aesthetics. Finally, the CBS‐TRV product was safe and well tolerated. Conclusions: The multiple active ingredients in CBS‐TRV target melanogenesis in a variety of ways, and both in vitro and clinical studies demonstrated significant improvements in skin tone and pigmentation.
- Open Access
- 14 January 2026
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal Open Forum
- Vol. 8, ojag075
The Efficacy and Safety of Radiofrequency Microneedling for Melasma: A Systematic Review and Qualitative Evidence Synthesis
Melasma is a chronic, relapsing hyperpigmentation disorder that is difficult to treat, particularly in Fitzpatrick skin types III-V, where energy-based devices frequently induce postinflammatory hyperpigmentation (PIH). Radiofrequency microneedling (RFMN) has emerged as a promising alternative because it targets dermal pathology while minimizing epidermal injury. Systematically evaluate the efficacy, safety, and mechanistic rationale of RFMN for melasma. A PRISMA 2020 compliant search of PubMed, Embase, Cochrane CENTRAL, and LILACS (2014-2025) identified clinical studies evaluating RFMN alone or in combination therapies. Risk of bias was assessed using Joanna Briggs Institute tools. Owing to clinical and methodological heterogeneity, a qualitative synthesis was performed. Across 12 included studies, RFMN consistently improved Melasma Area and Severity Index (MASI) or modified MASI scores and melanin indices, with effects maintained up to 6 months. Histological evidence demonstrated reductions in dermal senescence markers and partial restoration of basement-membrane integrity. RFMN also showed a favorable safety profile, with a low incidence of PIH in darker phototypes. Combination treatment, particularly with low-fluence Q-switched Nd:YAG laser produced greater pigment reduction than monotherapy. RFMN is an effective and safe modality for melasma, offering advantages over pigment-directed lasers by addressing dermal mechanisms and limiting PIH risk. It may serve as a first-line energy-based therapy. Level of Evidence:3 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
- 14 January 2026
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal Open Forum
- Vol. 8, ojag075
Open AccessThe Efficacy and Safety of Radiofrequency Microneedling for Melasma: A Systematic Review and Qualitative Evidence Synthesis
Melasma is a chronic, relapsing hyperpigmentation disorder that is difficult to treat, particularly in Fitzpatrick skin types III-V, where energy-based devices frequently induce postinflammatory hyperpigmentation (PIH). Radiofrequency microneedling (RFMN) has emerged as a promising alternative because it targets dermal pathology while minimizing epidermal injury. Systematically evaluate the efficacy, safety, and mechanistic rationale of RFMN for melasma. A PRISMA 2020 compliant search of PubMed, Embase, Cochrane CENTRAL, and LILACS (2014-2025) identified clinical studies evaluating RFMN alone or in combination therapies. Risk of bias was assessed using Joanna Briggs Institute tools. Owing to clinical and methodological heterogeneity, a qualitative synthesis was performed. Across 12 included studies, RFMN consistently improved Melasma Area and Severity Index (MASI) or modified MASI scores and melanin indices, with effects maintained up to 6 months. Histological evidence demonstrated reductions in dermal senescence markers and partial restoration of basement-membrane integrity. RFMN also showed a favorable safety profile, with a low incidence of PIH in darker phototypes. Combination treatment, particularly with low-fluence Q-switched Nd:YAG laser produced greater pigment reduction than monotherapy. RFMN is an effective and safe modality for melasma, offering advantages over pigment-directed lasers by addressing dermal mechanisms and limiting PIH risk. It may serve as a first-line energy-based therapy. Level of Evidence:3 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
- Open Access
- 27 December 2025
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 58 (2) , 63-69
Monopolar Radiofrequency for Dermal Prejuvenation: Scientific Rationale and Mechanisms of Action
Objectives: To summarize the scientific rationale for the use of the monopolar radiofrequency tissue tightening system (monoRF) for the prevention of dermal aging (termed prejuvenation). Materials and Methods: This narrative review summarizes the basic science of dermal aging and monoRF‐induced collagen remodeling and neocollagenesis. Studies supporting the mechanism of action of monoRF treatment and its use for prejuvenation are reviewed. Results: Dermal aging is largely attributed to the accumulation of fragmented collagen and depleted collagen levels. Collagen remodeling and neocollagenesis may be induced by monoRF treatment, resulting in immediate tissue tightening and subsequent collagen production, respectively. Preliminary data and expert opinion suggest that early and repeated intervention with monoRF may prevent progressive skin laxity via synergistic and cumulative effects. Conclusions: MonoRF treatment shows potential as a prejuvenation strategy, with preliminary evidence supporting that it induces collagen remodeling and neocollagenesis. Future research should focus on long‐term, prospective studies to determine the preventive benefits of consistent annual treatment for aging.
- 27 December 2025
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 58 (2) , 63-69
Open AccessMonopolar Radiofrequency for Dermal Prejuvenation: Scientific Rationale and Mechanisms of Action
Objectives: To summarize the scientific rationale for the use of the monopolar radiofrequency tissue tightening system (monoRF) for the prevention of dermal aging (termed prejuvenation). Materials and Methods: This narrative review summarizes the basic science of dermal aging and monoRF‐induced collagen remodeling and neocollagenesis. Studies supporting the mechanism of action of monoRF treatment and its use for prejuvenation are reviewed. Results: Dermal aging is largely attributed to the accumulation of fragmented collagen and depleted collagen levels. Collagen remodeling and neocollagenesis may be induced by monoRF treatment, resulting in immediate tissue tightening and subsequent collagen production, respectively. Preliminary data and expert opinion suggest that early and repeated intervention with monoRF may prevent progressive skin laxity via synergistic and cumulative effects. Conclusions: MonoRF treatment shows potential as a prejuvenation strategy, with preliminary evidence supporting that it induces collagen remodeling and neocollagenesis. Future research should focus on long‐term, prospective studies to determine the preventive benefits of consistent annual treatment for aging.
- Open Access
- 2 July 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (7)
Histologic Study of Abdominal Skin Treated With Mechanical Dermal Micro‐Coring Technology for Minimally Invasive Skin Removal
Background: Mechanical Dermal Micro‐Coring Technology (MCT; Ellacor System) achieves skin tightening and wrinkle reduction through direct mechanical excision of skin cores using hollow needles and collagen stimulation via the wound‐healing response.Aims: To evaluate histopathology and immunohistochemistry of the skin and subcutaneous tissue after a single and multiple treatments with MCT.Patients/Methods: In this single‐center pilot study, 6 female patients scheduled to undergo abdominoplasty were divided into 2 cohorts. Subjects in cohort 1 (safety cohort) received 1 MCT treatment at a depth of 4 mm, 5 mm, and 7 mm, each administered at 1 of 3 unique test areas, with tissue sampling/abdominoplasty 30 days after treatment. Subjects in cohort 2 received 1, 2, or 3 4 mm‐depth treatments at 1 of 3 unique test sites, with 30‐day intervals for > 1 treatment. Tissue sampling/abdominoplasty occurred 90 days after initial treatment. Histopathology was performed at a central laboratory, and biopsies were evaluated using H&E, Herovici, and Movat stains by blinded evaluators.Results: A robust increase in new collagen compared to the control tissue was observed for 1 to 3 treatments in all samples. There was no evidence of inflammation or scarring, consistent with earlier preclinical and clinical histology.Conclusions: MCT‐associated histological changes confirm that in addition to skin removal, treatment results in an increase in collagen and homogenization of the dermis in the treated area.
- 2 July 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (7)
Open AccessHistologic Study of Abdominal Skin Treated With Mechanical Dermal Micro‐Coring Technology for Minimally Invasive Skin Removal
Background: Mechanical Dermal Micro‐Coring Technology (MCT; Ellacor System) achieves skin tightening and wrinkle reduction through direct mechanical excision of skin cores using hollow needles and collagen stimulation via the wound‐healing response.Aims: To evaluate histopathology and immunohistochemistry of the skin and subcutaneous tissue after a single and multiple treatments with MCT.Patients/Methods: In this single‐center pilot study, 6 female patients scheduled to undergo abdominoplasty were divided into 2 cohorts. Subjects in cohort 1 (safety cohort) received 1 MCT treatment at a depth of 4 mm, 5 mm, and 7 mm, each administered at 1 of 3 unique test areas, with tissue sampling/abdominoplasty 30 days after treatment. Subjects in cohort 2 received 1, 2, or 3 4 mm‐depth treatments at 1 of 3 unique test sites, with 30‐day intervals for > 1 treatment. Tissue sampling/abdominoplasty occurred 90 days after initial treatment. Histopathology was performed at a central laboratory, and biopsies were evaluated using H&E, Herovici, and Movat stains by blinded evaluators.Results: A robust increase in new collagen compared to the control tissue was observed for 1 to 3 treatments in all samples. There was no evidence of inflammation or scarring, consistent with earlier preclinical and clinical histology.Conclusions: MCT‐associated histological changes confirm that in addition to skin removal, treatment results in an increase in collagen and homogenization of the dermis in the treated area.
- Open Access
- 5 December 2024
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 51 (4) , 403-408
In Vivo and Ex Vivo Evaluation of a Novel Method for Topical Delivery of Macromolecules Through the Stratum Corneum for Cosmetic Applications
BACKGROUND: Effective topical delivery of large/charged molecules into skin has always been challenging. Chemical penetration enhancers, organic substances that increase permeability of skin, have been in use for decades with variable success. One application of enhancers involves multilamellar vesicles composed of submicron emulsion droplets and micelles surrounded by concentric phospholipid bilayers. OBJECTIVE: This report introduces the next generation of multilamellar vesicles, termed Tiered-Release Vesicles (TRVs), as a new platform for topical delivery of macromolecules such as peptides and hyaluronic acid (HA). METHODS: Fluorescently labeled peptides and HA, diffusion cells, and confocal microscopy were employed to assess the penetration efficiency of macromolecules in TRV formulations using an ex vivo human skin model. Two in vivo studies utilized punch biopsies followed by histochemical staining and analysis. RESULTS: Based on fluorescent intensity, TRV formulations delivered a large peptide more completely (2–5 fold) into ex vivo human skin than optimized liposomes. The penetration of 2 HA species in TRV formulations was 3- to 13-fold higher than with a simple gel vehicle. In the case studies, reduction of solar elastosis was observed from a topical TRV formulation. CONCLUSION: Topical delivery of large peptides and HA into human skin using TRV technology has been demonstrated.
- 5 December 2024
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 51 (4) , 403-408
Open AccessIn Vivo and Ex Vivo Evaluation of a Novel Method for Topical Delivery of Macromolecules Through the Stratum Corneum for Cosmetic Applications
BACKGROUND: Effective topical delivery of large/charged molecules into skin has always been challenging. Chemical penetration enhancers, organic substances that increase permeability of skin, have been in use for decades with variable success. One application of enhancers involves multilamellar vesicles composed of submicron emulsion droplets and micelles surrounded by concentric phospholipid bilayers. OBJECTIVE: This report introduces the next generation of multilamellar vesicles, termed Tiered-Release Vesicles (TRVs), as a new platform for topical delivery of macromolecules such as peptides and hyaluronic acid (HA). METHODS: Fluorescently labeled peptides and HA, diffusion cells, and confocal microscopy were employed to assess the penetration efficiency of macromolecules in TRV formulations using an ex vivo human skin model. Two in vivo studies utilized punch biopsies followed by histochemical staining and analysis. RESULTS: Based on fluorescent intensity, TRV formulations delivered a large peptide more completely (2–5 fold) into ex vivo human skin than optimized liposomes. The penetration of 2 HA species in TRV formulations was 3- to 13-fold higher than with a simple gel vehicle. In the case studies, reduction of solar elastosis was observed from a topical TRV formulation. CONCLUSION: Topical delivery of large peptides and HA into human skin using TRV technology has been demonstrated.
- Open Access
- 18 August 2023
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (11) , 3026-3032
Treatment of mild to severe acne with 1726 nm laser: A safe alternative to traditional acne therapies
Introduction: Acne is the most common reason for dermatology consultation in adolescents and young adults. Consultation is often delayed despite unsuccessful self‐treatment. Postponing effective treatment places acne sufferers at higher risk for permanent acne scars and post‐inflammatory pigment changes.Aim: This review discusses clinical challenges with present therapeutic options for acne treatment and the role of a 1726 nm laser for acne.Methods: Current acne treatment guidelines were reviewed. A literature review was conducted for trials of light‐based acne therapy. The selectivity of previous light‐based therapies was reviewed.Results: Available acne therapy is effective, but treatment‐related side effects are common. Acne treatment guidelines do not include recommendations for light‐based treatments. Different types of light‐based treatments have been tried but until now no wavelength specifically targeted sebaceous glands.Conclusion: The 1726 nm laser is safe and effective for treating mild to severe acne in all Fitzpatrick skin types. Acne resolution is apparent within the first month and improves for up to 2 years beyond treatment.
- 18 August 2023
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 22 (11) , 3026-3032
Open AccessTreatment of mild to severe acne with 1726 nm laser: A safe alternative to traditional acne therapies
Introduction: Acne is the most common reason for dermatology consultation in adolescents and young adults. Consultation is often delayed despite unsuccessful self‐treatment. Postponing effective treatment places acne sufferers at higher risk for permanent acne scars and post‐inflammatory pigment changes.Aim: This review discusses clinical challenges with present therapeutic options for acne treatment and the role of a 1726 nm laser for acne.Methods: Current acne treatment guidelines were reviewed. A literature review was conducted for trials of light‐based acne therapy. The selectivity of previous light‐based therapies was reviewed.Results: Available acne therapy is effective, but treatment‐related side effects are common. Acne treatment guidelines do not include recommendations for light‐based treatments. Different types of light‐based treatments have been tried but until now no wavelength specifically targeted sebaceous glands.Conclusion: The 1726 nm laser is safe and effective for treating mild to severe acne in all Fitzpatrick skin types. Acne resolution is apparent within the first month and improves for up to 2 years beyond treatment.